ABSTRACT
The increasing use of multimodality cancer treatment has served to accentuate an interest in obtaining more detailed knowledge of the interaction and use of combined radiation and chemotherapy. Bleomycin (BLM) has been widely studied in this context. This is partly related to the major indication for BLM which is squamous cell carcinoma, a type of cancer which is frequently dominated by locallregional tumor extension, and is therefore a prime target for primary radiotherapy (especially head and neck and uterine cervix). In addition, BLM was one of the first drugs found to sensitize the effects of ionizing radiation.
